Patents by Inventor Howard Marcellus Johnson

Howard Marcellus Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7214367
    Abstract: The present invention includes interferon-tau (IFN?) pharmaceutical compositions useful for oral administration to treat cancers, autoimmune disorders (particularly multiple sclerosis), cell proliferative disorders and viral disease.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: May 8, 2007
    Inventors: Jeanne M. Soos, Joel Schiffenbauer, Howard Marcellus Johnson
  • Patent number: 6942854
    Abstract: The present invention includes interferon-tau (IFN?) pharmaceutical compositions useful for oral administration to treat cancers, autoimmune disorders (particularly multiple sclerosis), cell proliferative disorders and viral disease.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: September 13, 2005
    Assignee: University of Florida
    Inventors: Jeanne M. Soos, Joel Schiffenbauer, Howard Marcellus Johnson
  • Publication number: 20040146989
    Abstract: The present invention describes the production of interferon-&tgr; proteins and polypeptides derived therefrom. The antiviral and anticellular proliferation properties of these proteins and polypeptides are disclosed. One advantage of the proteins of the present invention is that they do not have cytotoxic side-effects when used to treat cells. Structure/function relationships for the interferon-&tgr; protein are also described. In one aspect, the invention includes ovine interferon-&tgr;. In another aspect the invention includes multiple forms of human interferon-&tgr;.
    Type: Application
    Filed: March 3, 2004
    Publication date: July 29, 2004
    Applicant: University of Florida
    Inventors: Howard Marcellus Johnson, Carol Hanlon Pontzer
  • Publication number: 20040086534
    Abstract: The present invention includes interferon-tau (IFN&tgr;) pharmaceutical compositions useful for oral administration to treat cancers, autoimmune disorders (particularly multiple sclerosis), cell proliferative disorders and viral disease.
    Type: Application
    Filed: October 27, 2003
    Publication date: May 6, 2004
    Applicant: University of Florida
    Inventors: Jeanne M. Soos, Joel Schiffenbauer, Howard Marcellus Johnson
  • Publication number: 20030012766
    Abstract: The present invention includes interferon-tau (IFNT) pharmaceutical compositions useful for oral administration to treat cancers, autoimmune disorders (particularly multiple sclerosis), cell proliferative disorders and viral disease.
    Type: Application
    Filed: December 21, 2001
    Publication date: January 16, 2003
    Applicant: University of Florida
    Inventors: Jeanne M. Soos, Joel Schiffenbauer, Howard Marcellus Johnson
  • Patent number: 6372206
    Abstract: The invention includes interferon-tau (IFN&tgr;) pharmaceutical compositions useful for oral administration to treat autoimmune disorders (particularly multiple sclerosis), cell proliferative disorders and viral disease.
    Type: Grant
    Filed: March 15, 1996
    Date of Patent: April 16, 2002
    Assignee: University of Florida
    Inventors: Jeanne M. Soos, Joel Schiffenbauer, Howard Marcellus Johnson
  • Publication number: 20020013452
    Abstract: The present invention describes the production of interferon-&tgr; proteins and polypeptides derived therefrom The antiviral and anticellular proliferation properties of these proteins and polypeptides are disclosed. One advantage of the proteins of the present invention is that they do not have cytotoxic side-effects when used to treat cells. Structure/function relationships for the interferon-&tgr; protein are also described. In one aspect, the invention includes ovine interferon-&tgr;. In another aspect the invention includes multiple forms of human interferon-&tgr;.
    Type: Application
    Filed: December 22, 2000
    Publication date: January 31, 2002
    Applicant: University of Florida
    Inventors: Howard Marcellus Johnson, Carol Hanlon Pontzer
  • Patent number: 6174996
    Abstract: The invention provides fusion proteins comprising an N-terminal region derived from an interferon-tau (IFN-&tgr;) polypeptide and a C-terminal region derived from another type I interferon polypeptide, such as IFN-&agr; or IFN-&bgr;. The fusion proteins exhibit reduced cytotoxicity as compared to the corresponding unmodified type I interferons.
    Type: Grant
    Filed: March 20, 1998
    Date of Patent: January 16, 2001
    Assignee: University of Florida
    Inventors: Howard Marcellus Johnson, Carol Hanlon Pontzer
  • Patent number: 6060450
    Abstract: Methods of treating autoimmune disorders, such as multiple sclerosis, are disclosed. The methods employ administration of interferon-tau (IFN.tau.) in a therapeutically-effective dose.
    Type: Grant
    Filed: May 25, 1999
    Date of Patent: May 9, 2000
    Assignee: University of Florida
    Inventors: Jeanne M. Soos, Joel Schiffenbauer, Howard Marcellus Johnson
  • Patent number: 5958402
    Abstract: The invention provides antitumor therapeutic methods employing bovine or ovine interferon-tau (IFN-.tau.) proteins and polypeptides. The IFN-.tau. proteins exhibit the antiviral and antiproliferative properties characteristic of type I interferons. An advantage of the invention is that IFN-.tau. has essentially no cytotoxic effects on treated cells as does, for example, IFN-.alpha..
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: September 28, 1999
    Assignee: University of Florida
    Inventors: Fuller Warren Bazer, Howard Marcellus Johnson, Carol Hanlon Pontzer, Troy Lee Ott, Gino Van Heeke
  • Patent number: 5942223
    Abstract: The invention provides antiviral therapeutic methods employing bovine or ovine interferon-tau (IFN-.tau.) proteins and polypeptides. The IFN-.tau. proteins exhibit the antiviral and antiproliferative properties characteristic of type I interferons. An advantage of the invention is that IFN-.tau. has essentially no cytotoxic effects on treated cells as does, for example, IFN-.alpha..
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: August 24, 1999
    Assignee: University of Florida
    Inventors: Fuller Warren Bazer, Howard Marcellus Johnson, Carol Hanlon Pontzer, Troy Lee Ott, Gino Van Heeke
  • Patent number: 5939286
    Abstract: The present invention describes hybrid interferon fusion polypeptides formed of a first segment that contains the N-terminal amino acid sequence of an interferon-tau polypeptide, and a second segment that contains the C-terminal amino acid sequence of a non-tau interferon type I polypeptide. The two segments are joined in the region of a mature interferon polypeptide between about residues 8 and 37. Also described are nucleic acid sequences encoding such interferon fusion polypeptides, expression vectors containing such sequences, and therapeutic applications of the interferon fusion polypeptides. The therapeutic applications include antiviral and anticellular proliferation applications. One advantage of the interferon fusion polypeptides of the present invention is that they do not have cytotoxic side-effects when used to treat cells.
    Type: Grant
    Filed: April 12, 1996
    Date of Patent: August 17, 1999
    Assignee: University of Florida
    Inventors: Howard Marcellus Johnson, Carol Hanlon Pontzer, Prem Shankar Subramaniam
  • Patent number: 5906816
    Abstract: Methods of treating autoimmune disorders, such as multiple sclerosis, are disclosed. The methods employ administration of interferon-tau (IFN.tau.) in a therapeutically-effective dose.
    Type: Grant
    Filed: March 16, 1995
    Date of Patent: May 25, 1999
    Assignee: University of Florida
    Inventors: Jeanne M. Soos, Joel Schiffenbauer, Howard Marcellus Johnson